Heron Therapeuti (HRTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Heron Therapeuti (HRTX) has a cash flow conversion efficiency ratio of 0.089x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.33 Million) by net assets ($14.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Heron Therapeuti - Cash Flow Conversion Efficiency Trend (1989–2024)
This chart illustrates how Heron Therapeuti's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read HRTX current and long-term liabilities for a breakdown of total debt and financial obligations.
Heron Therapeuti Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Heron Therapeuti ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SHANGH.DAZ.PUBL.UTIL.YC 1
F:6WL
|
N/A |
|
Digital Aria Co Ltd
KQ:115450
|
0.006x |
|
VietinBank Securities JSC
VN:CTS
|
0.060x |
|
Shanghai Jinqiao Export Processing Zone Development Co Ltd B
SHG:900911
|
-0.111x |
|
Sierra Madre Gold and Silver Ltd
V:SM
|
-0.004x |
|
Hathway Cable & Datacom Limited
NSE:HATHWAY
|
0.027x |
|
Kardan Israel Ltd
TA:KRDI
|
-0.050x |
|
Micro Contact Solution Co. Ltd
KQ:098120
|
0.033x |
Annual Cash Flow Conversion Efficiency for Heron Therapeuti (1989–2024)
The table below shows the annual cash flow conversion efficiency of Heron Therapeuti from 1989 to 2024. For the full company profile with market capitalisation and key ratios, see Heron Therapeuti market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-33.65 Million | $-22.53 Million | 0.669x | -61.31% |
| 2023-12-31 | $-33.97 Million | $-58.79 Million | 1.730x | +115.99% |
| 2022-12-31 | $13.57 Million | $-146.91 Million | -10.825x | -312.91% |
| 2021-12-31 | $77.57 Million | $-203.35 Million | -2.622x | -235.45% |
| 2020-12-31 | $236.49 Million | $-184.82 Million | -0.782x | -153.33% |
| 2019-12-31 | $403.83 Million | $-124.58 Million | -0.308x | +40.46% |
| 2018-12-31 | $370.16 Million | $-191.81 Million | -0.518x | +60.10% |
| 2017-12-31 | $131.14 Million | $-170.30 Million | -1.299x | -120.58% |
| 2016-12-31 | $-21.25 Million | $-134.10 Million | 6.310x | +1049.10% |
| 2015-12-31 | $118.11 Million | $-78.53 Million | -0.665x | +30.45% |
| 2014-12-31 | $63.06 Million | $-60.28 Million | -0.956x | -61.68% |
| 2013-12-31 | $68.94 Million | $-40.76 Million | -0.591x | -80.12% |
| 2012-12-31 | $51.82 Million | $-17.01 Million | -0.328x | +33.03% |
| 2011-12-31 | $15.75 Million | $-7.72 Million | -0.490x | +88.24% |
| 2010-12-31 | $1.32 Million | $-5.48 Million | -4.166x | -157.43% |
| 2009-12-31 | $6.80 Million | $-11.00 Million | -1.618x | +49.34% |
| 2008-12-31 | $7.60 Million | $-24.27 Million | -3.195x | -444.92% |
| 2007-12-31 | $29.47 Million | $-17.28 Million | -0.586x | -177.01% |
| 2006-12-31 | $12.06 Million | $9.18 Million | 0.761x | +162.74% |
| 2005-12-31 | $6.20 Million | $-7.53 Million | -1.213x | -121.81% |
| 2004-12-31 | $14.15 Million | $-7.74 Million | -0.547x | +5.57% |
| 2003-12-31 | $11.26 Million | $-6.53 Million | -0.579x | -74.54% |
| 2002-12-31 | $15.46 Million | $-5.13 Million | -0.332x | +1.97% |
| 2001-12-31 | $19.17 Million | $-6.49 Million | -0.339x | -129.91% |
| 2000-12-31 | $21.16 Million | $-3.12 Million | -0.147x | -194.53% |
| 1999-12-31 | $12.00 Million | $-600.00K | -0.050x | +51.67% |
| 1998-12-31 | $14.50 Million | $-1.50 Million | -0.103x | -427.59% |
| 1997-12-31 | $10.20 Million | $-200.00K | -0.020x | +98.39% |
| 1996-12-31 | $5.00 Million | $-6.10 Million | -1.220x | +25.36% |
| 1995-12-31 | $5.20 Million | $-8.50 Million | -1.635x | -124.28% |
| 1994-12-31 | $11.80 Million | $-8.60 Million | -0.729x | +34.59% |
| 1993-12-31 | $10.50 Million | $-11.70 Million | -1.114x | -477.14% |
| 1992-12-31 | $20.20 Million | $-3.90 Million | -0.193x | +83.74% |
| 1991-12-31 | $3.20 Million | $-3.80 Million | -1.188x | -120.04% |
| 1990-12-31 | $6.30 Million | $-3.40 Million | -0.540x | -34.92% |
| 1989-12-31 | $9.50 Million | $-3.80 Million | -0.400x | -- |
About Heron Therapeuti
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It … Read more